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Abstract
Background: Algorithms to diagnose gambiense human African trypanosomiasis (HAT, sleeping sickness) are often complex
due to the unsatisfactory sensitivity and/or specificity of available tests, and typically include a screening (serological),
confirmation (parasitological) and staging component. There is insufficient evidence on the relative accuracy of these
algorithms. This paper presents estimates of the accuracy of five algorithms used by past Me´decins Sans Frontie`res
programmes in the Republic of Congo, Southern Sudan and Uganda.
Methodology and Principal Findings: The sequence of tests in each algorithm was programmed into a probabilistic model,
informed by distributions of the sensitivity, specificity and staging accuracy of each test, constructed based on a literature
review. The accuracy of algorithms was estimated in a baseline scenario and in a worst-case scenario introducing various
near worst-case assumptions. In the baseline scenario, sensitivity was estimated as 85–90% in all but one algorithm, with
specificity above 99.9% except for the Republic of Congo, where CATT serology was used as independent confirmation test:
here, positive predictive value (PPV) was estimated at ,50% in realistic active screening prevalence scenarios. Furthermore,
most algorithms misclassified about one third of true stage 1 cases as stage 2, and about 10% of true stage 2 cases as stage
1. In the worst-case scenario, sensitivity was 75–90% and PPV no more than 75% at 1% prevalence, with about half of stage
1 cases misclassified as stage 2.
Conclusions: Published evidence on the accuracy of widely used tests is scanty. Algorithms should carefully weigh the use
of serology alone for confirmation, and could enhance sensitivity through serological suspect follow-up and repeat
parasitology. Better evidence on the frequency of low-parasitaemia infections is needed. Simulation studies should guide
the tailoring of algorithms to specific scenarios of HAT prevalence and availability of control tools.
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Introduction
The diagnosis of gambiense human African trypanosomiasis
(HAT, sleeping sickness) in routine conditions is complex [1].
Because infection prevalence is usually low (,1–2%), diagnostic
tests require a high sensitivity and specificity to achieve adequate
positive predictive value (PPV). Furthermore, accurate classifica-
tion into stage 1 (haemo-lymphatic) and 2 (meningo-encephalitic)
is crucial: the stage 1 treatment, pentamidine, is inefficacious for
stage 2 due to limited blood brain barrier penetration [2], while, of
the two stage 2 treatments, melarsoprol is highly toxic [3] and
eflornithine-nifurtimox is cumbersome to administer.
No single HAT diagnostic test currently offers satisfactory sensitivity
and specificity. Diagnostic algorithms therefore combine several tests
and feature a screening, confirmation and staging component. The
Card Agglutination Test for Trypanosomiasis (CATT) [4], highly
sensitive when performed in whole blood (CATT-wb) but insuffi-
ciently specific (,96%), is used for screening. After CATT-wb or
CATT plasma screening, various parasitological confirmation tests are
applied either alone or in sequence on blood and/or neck gland
aspirate, so as to maximise specificity while maintaining acceptable
levels of sensitivity. Various dilutions of the CATT in plasma (between
1:4 and 1:16) may also be performed ahead of parasitology to reduce
the number of individuals needing parasitological testing. Parasito-
logical positives (T+) undergo lumbar puncture and are classified as
stage 2 if parasites are found in cerebrospinal fluid (CSF), or if a given
threshold of CSF white blood cell (WBC) density (ranging from 5 to
20/mL) is exceeded [5]. Individuals with strong CATT reactions
(dilutions $1:4) but no parasitological evidence of infection (T2) are
generally considered serological suspects. Some control programmes
follow-up suspects for up to one year, repeating parasitological tests.
Others consider them non-cases or treat them presumptively. The
underlying infection prevalence affects the relative efficiency of these
different strategies [6,7,8].
The accuracy of HAT diagnostic algorithms has not been
documented in detail, partly because their complexity precludes
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straightforward analysis. Here, we present estimates of the
accuracy of five different diagnostic algorithms used by Me´decins
Sans Frontie`res (MSF) in past gambiense HAT control pro-
grammes using summary estimates of reported accuracy of
individual HAT tests and a probabilistic model.
Methods
Description of the MSF algorithms
The five algorithms (shown in Figures 1 to 5) were used in
projects in the Republic of Congo (Gamboma, Plateaux Region,
2001–2003; Mossaka, Cuvette Region, 2003–2005; Nkayi,
Bouenza Region, 2003–2005); Southern Sudan (Kiri, Kajo Keji
County, Central Equatoria, 2000–2007); and Uganda (Adjumani
District, 1991–1996; Arua and Yumbe Districts, 1995–2002). The
Southern Sudan project made progressive modifications to its
algorithm, but only the first (old) and the last (new) algorithms used
by that project are assessed here.
As initial screening tests, all algorithms used the CATT-wb, and
the Congo and Sudan algorithms also used systematic gland
palpation among CATT-wb negatives. Parasitology (performed on
the field during active screening) included microscopic examina-
tion of aspirate from punctured palpable cervical glands (GP) [9],
done in all algorithms, complemented by capillary tube centrifu-
gation (CTC or the Woo test [10]; theoretical detection limit 100
parasites/mL, reported limit 500–600/mL) or the Quantitative
Buffy Coat (QBC; 15/mL, 15–300/mL) technique [11] in
Southern Sudan, and the mini anion exchange centrifugation
technique (mAECT; 5/mL, 15–100/mL) [12] or QBC in Uganda.
Furthermore, the Southern Sudan algorithms used the QBC as the
parasitological test during passive screening (testing of patients
spontaneously presenting to a HAT treatment centre), and the
CTC during active screening.
All programmes initially did systematic follow-up of serological
suspects, but this was eventually stopped in Congo and Kiri due to
low follow-up rates and high workload; in Kiri, this strategy was
replaced with systematic treatment of suspects positive at CATT
dilution$1:16, later restricted to villages with observed prevalence
$2%. The Congo algorithm treated CATT$1:8 positive but T2
individuals as cases regardless of CSF WBC density.
Staging of HAT in T+ (and CATT$1:8 positive in Congo)
individuals was done at the fixed treatment centre by lumbar puncture
and double centrifugation of the CSF (CSF-DC). If CSF-DC revealed
no parasites, staging was based on WBC density thresholds. These
thresholds were either .5 or .10/mL as per country guidelines [13].
With the exception of Congo, all algorithms performed LP in
T2 but CATT dilution ($1:4 or $1:16) positive individuals for
simultaneous confirmation and staging. For these patients, the
WBC density threshold was increased to .20/mL; furthermore,
those not meeting stage 2 criteria were not automatically
considered stage 1 cases, but rather suspects, creating a differential
in sensitivity according to whether the case was stage 1 or stage 2.
Differences among algorithms reflect adherence to national HAT
guidelines (for example, in Congo the WBC threshold was higher);
the availability on the market of certain parasitological tests at
different times (for example, the mAECT is a more recent
development and interruptions in the production line have
occurred); different operational strategies (in Congo MSF aimed
to cover a large, sparse territory with single active screening visits
with the overriding objective of maximum coverage and thus
sensitivity); and, to some extent, decisions by individual programme
coordinators or MSF sections (in the past decade, an inter-sectional
working group has worked toward greater standardisation).
Literature review of the accuracy of individual tests
Medline PubMed searches were conducted with the MeSH
terms ‘‘Trypanosomiasis, African/diagnosis’’, and with combina-
tions of [‘‘trypanosomiasis’’/‘‘trypanosomosis’’/‘‘trypanosome’’/
‘‘sleeping sickness’’] and [‘‘screening’’/‘‘confirmation’’/‘‘diagno-
sis’’/‘‘stage’’/‘‘staging’’/‘‘diagnostic’’/‘‘card agglutination test’’/
‘‘CATT’’/‘‘gland’’/‘‘woo’’/‘‘capillary tube centrifugation’’/
‘‘mini-anion exchange’’/‘‘buffy coat’’/‘‘cerebrospinal fluid’’/
‘‘lumbar puncture’’/‘‘white blood cell’’/‘‘leucocyte’’/‘‘polymerase
chain reaction’’/‘‘IgM’’]. The bibliographic trail of each paper
was followed to its exhaustion where appropriate, and several
reviews [1,14,15] were consulted. The search was limited to the
period from January 1970 to June 2007.
Studies were included in the review only if they had tested the
accuracy of T. brucei gambiense diagnosis among untreated cases, and
if they featured an acceptable diagnostic gold standard, defined as
follows: (i) for screening and confirmation tests, testing with GP or
CTC and at least one of the following: QBC, mAECT, enzyme
linked immunosorbent assay (ELISA), Kit for In Vitro Identification
(KIVI), or animal inoculation; (ii) for the specificity of the CATT-
wb, testing of individuals not living in HAT endemic areas; (iii) for
staging tests, testing of CSF, among T+ cases only, with polymerase
chain reaction (PCR), in vitro culture, or immunological markers of
infection including raised IgM levels [16].
Studies that were not designed for testing validity, but contained
sufficient data for accuracy estimation, were included. In some
studies, we considered the experimental test used by investigators
as the gold standard, and vice versa: in these cases, we inverted the
two and re-calculated accuracy. The accuracy of CATT dilutions
was only evaluated from studies among CATT-wb positives, since
the algorithms only performed such dilutions after the CATT-wb
screening, i.e. the parameter of interest was relative accuracy
compared to the CATT-wb. Reports of CATT accuracy from foci
where parasites frequently lack the LiTat1.3 gene [1] (Nigeria,
Cameroon) were excluded.
Details on studies meeting inclusion criteria are provided in Text
S1, and the amount of information available for each diagnostic test
Author Summary
Gambiense human African trypanosomiasis (HAT, sleeping
sickness) usually features low prevalence. The two stages
of the disease require different treatments, and stage 2 is
fatal if untreated. HAT diagnosis must therefore be highly
sensitive (i.e., detect as many true cases as possible) and
specific (i.e., minimize false positives). HAT diagnostic
algorithms are complex and involve several tests to screen
for, confirm and stage infection. We analyzed five
algorithms used by Me´decins Sans Frontie`res HAT
programmes. We combined published data on the
accuracy of each test in the algorithm with a computer
program that simulates all possible algorithm branches.
We found that all algorithms had reasonable sensitivity
(85–90%); specificity was high (.99.9%) except for the
Republic of Congo, where confirmation did not rely on
microscopic evidence, resulting in frequent false positives
(but also higher sensitivity). Algorithms misclassified about
one third of stage 1 cases as stage 2, but stage 2
classification was highly accurate. The use of serology
alone for confirmation merits caution. HAT diagnosis could
be made more sensitively by following up serological
suspects and repeating microscopic examinations. Com-
puter simulations can help to adapt algorithms to local
conditions in each HAT programme, such as the preva-
lence of infection and operational constraints.
Accuracy of Trypanosomiasis Diagnostic Algorithms
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is summarised in Table 1. An additional nine studies were excluded
from either the sensitivity or specificity reviews because the gold
standard was inadequate [17,18,19,20,21,22] or the study design
did not allow for diagnostic accuracy estimation [23,24,25]. One
study of staging accuracy [26] was excluded because the IgM
threshold used was deemed too high.
Probability distributions of test accuracy
Individual estimates of test accuracy were combined into
probability distributions for further modelling. Distributions for
the accuracy of successive CATT dilutions were constructed by
fitting polynomial functions to plots of available sensitivity or
specificity point estimates versus the natural logarithm of the
dilution, with observations weighted proportionately to each
study’s sample size (Figure S1a, Figure S1b in Text S1). The
fitted values and their 95% confidence intervals at each dilution
of interest were used to construct binomial distributions.
Probability distributions for other tests were constructed as follows.
First, exact binomial probability distributions were built around the
point estimate of each study. Second, each study’s distribution was
weighted proportionately to the study’s sample size. Third, the
individual study distributions were summed, and the resulting
distribution was scaled so that the area under the curve totalled unity.
An illustration is provided for the CTC (Figure 6).
For the QBC, there was only one published estimate of sensitivity,
from a small study (n = 11). The technique is reported to have similar
Figure 1. Diagnostic algorithm used in the Gamboma, Mossaka and Nkayi, Republic of Congo programmes. Hexagonal boxes indicate
tests. Square, blue-shaded boxes indicate points at which a decision on the patient is reached.
doi:10.1371/journal.pntd.0001233.g001
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sensitivity to the mAECT [12,20], which is plausible given their
comparable detection limits: therefore, the same distribution was used
for the QBC as for the mAECT.
Finally, the specificity of parasitological tests for confirmation was
fixed at 100%: the presence of trypanosomes is unequivocal, and
trained microscopists should ordinarily not report false positives.
Alternative worst-case scenario
For the purpose of planning for long-term transmission control, it
might be useful to consider minimum requirements to guarantee
success even if conditions in reality are less favourable than published
evidence suggests. Accordingly, more conservative accuracy estimates
were obtained by applying a set of worst-case scenario assumptions
(Table 2). These assumptions sought to account for the fact that even
the most sensitive tests (QBC, mAECT) are likely to miss low
parasitaemias (,5–15 trypanosomes/mL). Studies of T- suspects,
based on PCR assays for T. brucei s.l. [27] featuring 100% specificity in
controls from non-endemic regions [28,29,30,31], have reported 22%
positivity in Cameroon [30]; 19–37% in the Ivory Coast [29]; and 15%
in Equatorial Guinea and Angola [32].
Figure 2. Diagnostic algorithm used in the Kiri, Southern Sudan programme (beginning of programme). Hexagonal boxes indicate
tests. Square, blue-shaded boxes indicate points at which a decision on the patient is reached.
doi:10.1371/journal.pntd.0001233.g002
Accuracy of Trypanosomiasis Diagnostic Algorithms
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Probabilistic model
R software was used to program the different algorithms into a
sequence of conditional probabilities, so as to calculate sensitivity,
specificity, and staging accuracy (defined as the probability of being
correctly classified into either stage) of the algorithm as a whole,
given any values of accuracy for individual tests. Equations for the
accuracy estimation of each algorithm are provided in Text S1.
Because some algorithms used CSF-DC and WBC count for
confirmation as well as staging, sensitivities vary according to
whether the true positive case is in stage 1 or stage 2, and were thus
computed separately. Furthermore, scenarios with and without
follow-up of serological suspects were evaluated, i.e. assuming none
or all such cases are re-tested according to the stipulated schedule (in
practice, the follow-up rate varies by site [33]).
The sensitivity and specificity of any given test for the baseline
scenario were specified by the probability distributions constructed
above, summarised in Table 3. The model was run 10 000 times for
each algorithm and for both the baseline and worst-case
(incorporating the adjustments in Table 2) scenarios. During each
run, a random value was sampled from each input probability
distribution. Median sensitivity, specificity and staging accuracy
were then computed based on the output distribution of results from
the 10 000 runs, along with their 95% percentile interval (i.e. the
interval comprising 95% of the run results).
The resulting negative and positive predictive values (NPV, PPV)
were also calculated assuming 0.1%, 1% or 10% infection
prevalence. The ratio of non-cases needlessly treated to true cases
treated (over-treatment ratio) was also calculated for each algorithm
Figure 3. Diagnostic algorithm used in the Kiri, Southern Sudan programme (end of programme). Hexagonal boxes indicate tests.
Square, blue-shaded boxes indicate points at which a decision on the patient is reached.
doi:10.1371/journal.pntd.0001233.g003
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and prevalence scenario, assuming a stage 1 to stage 2 ratio of two
among prevalent infections detected actively in never-before screened
communities, consistent with empirical observations in most MSF
projects (Francesco Checchi, unpublished observations). However,
this assumption is of negligible importance: the converse (a ratio of
0.5) would result in nearly identical estimates (data not shown), since
differences in sensitivity between stage 1 and stage 2 are small and of
limited influence given that HAT is a low-prevalence infection (PPV
and NPV are largely determined by specificity).
Results
Sensitivity, specificity and staging accuracy
Accuracy estimates for the baseline scenario are shown in
Table 4. Sensitivity including suspect follow-up was highest in
Congo, and considerably lower than elsewhere for the new Kiri
algorithm, which screened out cases negative at a high CATT
dilution (,1:16). Specificity was 99.9% or 100% everywhere with
the exception of Congo (99.1%).
The theoretical sensitivity gain from suspect follow-up was
considerable: about 3–4% everywhere, but 10–20% in Kiri, where
T2, CATT dilution $1:4 positives were followed up. There was no
appreciable specificity cost from suspect follow-up. Algorithms were
predicted to misclassify about one in ten of the stage 2 cases as stage 1;
conversely, about one third of stage 1s were treated as stage 2, with
the exception of Congo, where the higher WBC threshold (.10/mL)
resulted in a small increase in stage 2 misclassification, but only 13%
stage 1 misclassification (note however the wide percentile intervals).
In the worst-case scenario (Table 5), sensitivity was 10–15%
lower everywhere except for Congo (where conservative assump-
Figure 4. Diagnostic algorithm used by Adjumani programme, Uganda. Hexagonal boxes indicate tests. Square, blue-shaded boxes indicate
points at which a decision on the patient is reached.
doi:10.1371/journal.pntd.0001233.g004
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tions mostly did not affect the CATT$1:8 dilution test), and
around 50% for the new Kiri algorithm. Specificity decreased
below 99.8% except for the new Kiri algorithm. Stage misclas-
sification affected more than half of stage 1 cases.
Overall, the Congo and new Kiri algorithms offered opposite
extreme characteristics: the former guaranteed very high sensitiv-
ity but had low specificity; the latter was highly specific even under
worst-case scenario assumptions, but had low sensitivity.
Predictive values and over-treatment ratios
NPV was uniformly high (Table 6). Because of low specificity,
the predicted PPV of the Congo algorithm was also low at most
plausible prevalence levels (,50% for any prevalence ,1%),
resulting in a high over-treatment ratio. Because PPV is extremely
sensitive to minimal changes in specificity, predicted PPVs with
high specificity values should be interpreted with caution (e.g. in
Uganda, median specificity was 99.94%, but was rounded to
Figure 5. Diagnostic algorithm used by Arua-Yumbe programme, Uganda. Hexagonal boxes indicate tests. Square, blue-shaded boxes
indicate points at which a decision on the patient is reached.
doi:10.1371/journal.pntd.0001233.g005
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99.9%, which results in a 20% decrease in PPV at prevalence
0.1%). Only the new Kiri algorithm achieved perfect PPV at any
prevalence (however, the resultant elimination of over-treatment
was counterbalanced by a policy of treating serological suspects
with pentamidine in high-prevalence villages).
Discussion
Interpretation of findings
This study suggests that diagnostic algorithms previously used
by MSF had a sensitivity of 85–90% in a baseline scenario
analysis, except for an algorithm in Southern Sudan in which only
individuals CATT$1:16 positive underwent blood and CSF
parasitological exams. At least theoretically, and irrespective of its
efficiency and cost-effectiveness, the follow-up of serological
suspects does yield an appreciable increase in sensitivity; however,
this benefit may largely be negated in the field because of low
suspect follow-up rates (suspect follow-up is costly as it often
requires active patient tracing). Among other studies of HAT
diagnostic algorithms (all starting with CATT-wb positivity),
Miezan et al. [34] found sensitivities of 94.8%, 98.3% and
91.4% for the [GP+CTC+CSF-DC], [GP+mAECT+CSF-DC]
and [GP+mAECT] combinations, respectively; Robays et al.
projected sensitivity 76.6% for the mAECT [35]; Lutumba et al.
estimated a sensitivity of 86% for the [GP+CTC] combination
[36].
Table 1. Number of reports of sensitivity, specificity and staging accuracy contained in studies included in the review, by
diagnostic test.
Diagnostic test Sensitivity reports Specificity reports
Number References Number References
CATT-wb 8 [45,46,47,48,49,50,51,52] 11 (8 used only
in worst-case
scenario)
[45,53] ([45,46,47,48,49,51,52,54])
CATT dilution 1:2{ 3 [4,54,55] 2 [54,55]
CATT dilution 1:4{ 5 [4,48,54,55,56] 2 [54,55]
CATT dilution 1:5{ 2 [34,51] 0
CATT dilution 1:8{ 4 [4,54,55,56] 2 [54,55]
CATT dilution 1:10{ 2 [34,51] 0
CATT dilution 1:16{ 4 [4,54,55,56] 2 [54,55]
CATT dilution 1:20{ 2 [34,51] 0
CATT dilution 1:32{ 4 [4,54,55,56] 2 [54,55]
CATT dilution 1:40{ 2 [34,51] 0
CATT dilution 1:64{ 3 [4,54,56] 1 [54]
CATT dilution 1:80{ 2 [34,51] 0
CATT dilution 1:128{ 1 [56] 0
CATT dilution 1:160{ 2 [34,51] 0
CATT dilution 1:320{ 1 [51] 0
GP 4 [34,55,57,58] 0
CTC 4 [34,55,58,59] 1 [60]
mAECT 3 [34,55,58] 0
QBC 1 [58] 0
CSF-DC (if case is in stage 1 {) 5 (1 used only
in worst-case
scenario)
[34,60,61,62] ([16]) 5 (1 used only
in worst-case
scenario)
[34,60,61,62] ([16])
CSF-DC (if case is in stage 2 {) 5 [16,34,60,61,62]
WBC density .20/mL (if case is in stage 1 {) 4 [16,61,62,63] 4 [16,61,62,63]
WBC density .20/mL (if case is in stage 2 {) 4 [16,61,62,63]
Number of stage 1 accuracy reports Number of stage 2 accuracy reports
Number References Number References
CSF-DC 5 (1 used only
in worst-case
scenario)
[34,60,61,62] ([16]) 5 [16,34,60,61,62]
WBC density .5/mL 4 [60,61,62,63] 5 [25,60,61,62,63]
WBC density .10/mL 2 [61,63] 2 [61,63]
WBC density .20/mL 4 [16,61,62,63] 4 [16,61,62,63]
{Among CATT-wb positives only.
{Stage 1 or 2 as defined according to the gold standard adopted for this study (see Methods).
doi:10.1371/journal.pntd.0001233.t001
Accuracy of Trypanosomiasis Diagnostic Algorithms
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All algorithms also appeared to have an acceptable PPV except for
Congo’s, where serological diagnosis probably resulted in a high
frequency of stage 1 false positives (see below). Furthermore, reliance
on the conventional HAT staging approach (parasitology and WBC
threshold of.5 leucocytes/mL) may have captured the vast majority
of stage 2 cases but misclassified about one third of stage 1 cases as
stage 2: this harm-benefit ratio is nonetheless likely to be favourable,
since the risk of death from undetected stage 2 HAT is probably
100% [37], while the risk of death due to stage 2 drug toxicity among
stage 1 cases misclassified as stage 2 is less than 5%, and ,2%
wherever eflornithine-nifurtimox has replaced melarsoprol as first-
line treatment. Misclassification of stage 2 cases could partly be
avoided by introducing some clinical criteria in the algorithm (e.g.
patients with typical signs and symptoms of stage 2, and who are
classified as stage 1, should be retested or treated empirically).
Our findings refer to the relatively favourable conditions of HAT
diagnosis provided for by a well-resourced non-governmental
organisation with access to the best available technology, ability to
train and supervise staff and considerable field logistics. Many HAT
programmes, particularly those implemented by national control
programmes after humanitarian agencies and other donors
discontinue support, do not dispose of such resources, and must
use simpler algorithms, sometimes relying on blood smears and
cervical node microscopy alone for parasitological testing in remote
active screening campaigns. Such simple algorithms are likely to
feature a much lower accuracy than those we have evaluated here:
national programmes should receive continued technical and
material support in order to offer adequate HAT diagnosis.
Plausibility of worst-case scenario assumptions
While worst-case scenario estimates may be implausibly low, the
question of whether current tests miss a larger proportion of cases than
currently thought, as suggested by PCR data, should be explored
further. While in non-endemic areas PCR appears extremely specific,
among CATT-wb negatives in endemic areas PCR positives do occur:
4/73 (5.5%) in Ivory Coast [29], 3/222 (1.4%) in Cameroon [30], and
1/36 (2.8%) in Equatorial Guinea and Angola [32]. These observations
could be explained as (i) false PCR positives due to cross-reactivity with
other antigens, including DNA from non-gambiense T. brucei s.l.
transiently infecting the host; or (ii) true T. b. gambiense infections
undetectable by other tests due to low parasite density.
The former explanation is supported by the finding that a study
in an Ivory Coast focus employing a PCR assay specific for T. b.
gambiense yielded no PCR positives [31], while all studies with high
PCR positivity relied on non-gambiense specific assays. However,
the Ivory Coast assay used had a detection limit comparable to the
mAECT, and may have failed to detect cases of low parasitaemia
(by contrast, the non-gambiense specific Cameroon assay
developed by Penchenier et al. [30] has a reported limit of 1/mL).
The latter explanation requires the existence of infections that
maintain extremely scanty parasitaemia and are not or only mildly
pathogenic [37].
Better evidence should come from the development of T.brucei
gambiense specific molecular assays that also have a detection limit
appreciably lower than parasitology, and their application to long-
term follow-up of T2 serological suspects [38]. Estimating the true
sensitivity of tests would require knowledge of the typical
distribution of parasitaemias in human hosts, but this is difficult
to measure precisely because of the detection limit of current
methods (presumably, if a large database of known parasite
densities were assembled, the resulting distribution could be
treated as truncated, and extrapolated below the minimum
detection limit). Data on cattle are available, but may not apply
to humans due to differences in host-parasite interactions.
Figure 6. Steps to build a probability distribution of CTC test sensitivity. Each report is denoted by the name of the first author and the year
of publication. In step three, the final probability distribution is then normalised to unity (i.e. the total probability = 1).
doi:10.1371/journal.pntd.0001233.g006
Table 2. Assumptions made in the worst-case scenario analysis.
Parameter Rationale Adjustment to baseline scenario
Sensitivity of CATT-wb PCR evidence suggests some CATT-wb negative,
T2 individuals may in fact be infected (see Discussion:
Plausibility of worst-case scenario assumptions)
1–5% lower than the baseline scenario (uniform
distribution), based on range reported in the
literature (see Discussion)
Sensitivity of parasitological tests performed
after a first negative parasitological test (e.g.
mAECT after negative CTC)
Average parasitaemia among cases not detected by the
first test is probably lower: a greater proportion of those
tested by the second test has parasitaemia below the test’s
detection limit
20–50% lower than the baseline scenario (uniform
distribution); as no evidence was found, this range
is assumed to be plausible
Sensitivity of algorithm among CATT-wb
positive cases (i.e. of confirmation step)
PCR evidence suggests some infections are below the
detection limit of parasitological tests (see Methods:
Alternative worst-case scenario)
10–20% lower than the baseline scenario (uniform
distribution), based on range of PCR positivity
among T2 suspects reported in the literature (see
Methods)
Specificity of CATT-wb Results from non-HAT exposed populations may be
unrepresentative (e.g. HAT-exposed populations may
also have higher prevalence of parasitic infections, such
as P. falciparum, that may cross-react with the CATT [56])
Re-constructed probability distribution by including
reports from apparently HAT-negative controls in
HAT-endemic sites
Specificity of GP, CTC, mAECT, QBC, CSF-DC Rare false positives could occur due to microscopic
artefacts, e.g. microfilaria, or clerical mistakes
99.5–100.0% of the baseline scenario (uniform
distribution); as no evidence was found, this range
is assumed to be plausible
Staging accuracy of CSF-DC for stage 2 One study [16] reported much lower accuracy based on
a gold standard consisting of various markers of
neuro-inflammation including intrathecal IgM
Specificity from study in question (73.3%) adopted
instead of those used in the baseline scenario
Sensitivity of CSF-DC for confirmation,
if case is in stage 1
False CSF-DC positives would lead to confirmation of a
patient as a case, even if the patient is in fact in stage 1
Sensitivity of 26.7% ( = 100%273.3%) adopted,
based on the above study
doi:10.1371/journal.pntd.0001233.t002
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In the mean time, we suggest that worst-case assumptions be
used for determining requirements of programmes aiming for
long-term control or local elimination.
Implications for field diagnosis
Specificity is key to maximising PPV. Very low HAT infection
prevalence (e.g. ,0.2%) is common in many communities
screened actively, implying poor PPV, considerable over-treat-
ment, and inflated prevalence estimates for even the most specific
algorithms considered here. However, in many programmes the
majority of cases are detected passively. The prevalence of
infection among individuals spontaneously presenting to the fixed
HAT centre is higher, and was above 2% in all MSF programmes
where these algorithms were used (Table 7). These observed
prevalence figures suggest that PPV is generally high during
passive screening (.95% everywhere except Congo).
Assuming reasonable laboratory quality, all parasitological tests
are likely to be 100% specific, and reliance on these alone for
confirmation should guarantee perfect PPV. By contrast, this study
suggests that use of a CATT 1:8 dilution positive test as criterion for
confirming infection, irrespective of parasitological results, entails a
heavy specificity price. Field data appear to corroborate this
finding. Among true cases, the proportion diagnosed via the CATT
1:8 dilution (serologically) should in theory not depend on HAT
stage (serological tests in blood are believed by some to be less
sensitive in stage 2, but no published evidence for this was found).
On the other hand, among false positives, most cases diagnosed
serologically would be classified as stage 1, since during staging all
would be negative for CSF-DC and most would have normal WBC
density. A preponderance of stage 1 is thus indicative of
considerable over-diagnosis. Within the three Congo sites,
serological cases were 1559/2857 (54.6%) of naı¨ve (previously
untreated) cases, of which 1364/1559 (87.5%) were in stage 1,
compared to 624/1298 (48.1%) of cases confirmed parasitologi-
cally. Furthermore, serological cases were 244/629 (38.8%) of cases
detected passively, and 1244/2152 (57.8%) of cases detected
actively. In a simple logistic regression model, both stage 1
classification and active screening were associated with serological
diagnosis (odds ratios 7.45 [95%CI 6.13–9.05] and 1.35 [95%CI
1.10–1.66] respectively). Altogether, these observations suggest
considerable over-diagnosis of HAT (nearly all classified as stage 1)
in Congo. Inojosa et al. found a similarly low PPV of an algorithm
based on the CATT 1:8 dilution in Angola (13.2% with 0.07%
prevalence) [22]. Diagnosis through CATT serology does improve
sensitivity considerably; however, we suggest that its use be
restricted to (i) passive screening and (ii) active screening in remote
communities with suspected high prevalence where there is likely to
be only one opportunity for screening, and where melarsoprol is not
used as first-line therapy or the algorithm minimises misclassifica-
tion of stage 1 cases. Furthermore, we recommend use of a 1:16
dilution in lieu of 1:8. Control programs that use algorithms with
serological criteria aim to reduce transmission at the expense of
Table 3. Input parameter values for baseline scenario.
Screening or confirmation test
Mean* or median sensitivity
% (95% interval)
Mean* or median specificity
% (95% interval)
CATT-wb 91.2 (78.1–99.8) 97.4 (93.8–99.2)
CATT 1:4 dilution{ 97.7* (92.8–100.0) 39.2* (29.6–48.8)
CATT 1:8 dilution{ 85.1* (81.0–89.2) 63.6* (55.2–72.0)
CATT 1:16 dilution{ 59.5* (55.2–63.7) 81.8* (72.0–91.6)
GP{ 58.5 (43.1–77.0) 100.0
CTC 56.0 (38.9–79.9) 100.0
mAECT 76.9 (68.8–92.1) 100.0
QBC 76.9 (68.8–92.1) 100.0
CSF-DC if case is in stage 1 2.4 (0.0–13.6) " 100.0
CSF-DC if case is in stage 2 68.8 (50.6–85.2)
WBC density .20/mL if case is in stage 1 3.6 (0.1–17.8) " 96.2 (82.0–99.7)
WBC density .20/mL if case is in stage 2 67.3 (32.3–75.5)
Staging test
Median accuracy of stage 1 classification %
(95% interval)
Median accuracy of stage 2 classification %
(95% interval)
CSF-DC 97.4 (86.2–99.8) " 68.8 (50.6–85.2)
WBC density .5/mL 69.8 (45.1–87.8) 74.4 (46.3–89.8)
WBC density .10/mL 90.3 (58.4–98.4) 65.6 (39.1–80.7)
WBC density .20/mL 96.2 (82.0–99.7) " 67.3 (32.3–75.5)
Prevalence of palpable cervical glands Prevalence in % (range{) Distribution Notes
Among true positives 50.0–100.0 uniform [1,64]
Among true negatives 0.0–10.0 uniform Based on prevalence of glands amongCATT-wbnegative
non-cases in HAT foci under control in DRC [65,66]
{Among CATT-wb positives.
{Among persons with palpable glands.
"Accuracy is ,100% in these cases because of a study reporting a small percentage of false positives, based on the gold standard stage definition adopted in this study
(see Methods). If the patient is in fact a true case and his or her infection is not confirmed by any other test, these false positives would make a very small, serendipitous
sensitivity contribution. Conversely, they would result in a less than perfect staging accuracy.
doi:10.1371/journal.pntd.0001233.t003
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over-treatment. However, the individuals diagnosed solely on
serology should not be regarded as HAT cases for the calculation of
prevalence, as this would result in an overestimation of disease
burden and obscure prevalence changes over time. They should be
clearly distinguished from genuine cases in programme reporting
and surveillance.
Table 4. Estimated sensitivity, specificity and accuracy of staging of HAT diagnostic algorithms (baseline scenario).
Accuracy indicator
Gamboma, Mossaka,
Nkayi, Republic
of Congo
Kiri, Sudan (old
algorithm)
Kiri, Sudan (new
algorithm)
Adjumani,
Uganda
Arua/Yumbe,
Uganda
Screening and confirmation of infection, assuming perfect follow-up of suspects{
Sensitivity if case is stage 1 (%) 95.2 (87.6–99.8) QBC: 93.8 (84.6–99.3)
CTC: 93.8 (84.4–99.2)
QBC: 70.3 (57.6–83.2)
CTC: 69.9 (56.5–83.2)
89.0 (75.5–98.8) 89.3 (76.0–98.5)
Sensitivity if case is stage 2 (%) 95.2 (87.6–99.8) QBC: 93.8 (84.7–99.3)
CTC: 93.9 (84.9–99.3)
QBC: 70.4 (57.9–83.2)
CTC: 70.3 (57.8–83.2)
89.6 (76.5–99.1) 89.7 (76.5–99.0)
Specificity (%) 99.1 (97.7–99.7) QBC: 99.9 (99.6–100.0)
CTC: 99.9 (99.6–100.0)
QBC: 100.0 (99.9–100.0)
CTC: 100.0 (99.9–100.0)
99.9 (99.6–100.0) 99.9 (99.6–100.0)
Screening and confirmation of infection, assuming no follow-up of suspects
Sensitivity if case is stage 1 (%) 92.1 (84.2–97.1) QBC: 83.9 (72.7–93.2)
CTC: 73.8 (60.1–87.3)
QBC: 64.1 (51.1–79.2)
CTC: 58.0 (43.5–75.0)
85.3 (72.3–96.1) 85.6 (72.5–96.0)
Sensitivity if case is stage 2 (%) 92.1 (84.2–97.1) QBC: 92.0 (82.5–97.8)
CTC: 90.0 (80.0–96.5)
QBC: 69.1 (56.7–82.3)
CTC: 67.9 (55.2 (81.4)
88.8 (75.9–98.3) 89.1 (75.8–98.4)
Specificity (%) 99.1 (98.0–99.7) QBC: 99.9 (99.7–100.0)
CTC: 99.9 (99.7–100.0)
QBC: 100.0 (99.9–100.0)
CTC: 100.0 (99.9–100.0)
99.9 (99.7–100.0) 99.9 (99.7–100.0)
Accuracy of staging
Probability of being correctly
classified as stage 1 (%)
87.0 (61.1–95.9) QBC: 66.5 (43.9–84.3)
CTC: 65.9 (43.2–83.3)
QBC: 66.6 (44.1–84.7)
CTC: 66.0 (43.6–83.3)
66.9 (43.9–85.0) 67.0 (44.1–84.9)
Probability of being correctly
classified as stage 2 (%)
89.0 (79.0–94.8) QBC: 92.9 (82.2–97.7)
CTC: 93.7 (84.2–98.0)
QBC: 92.3 (81.9–97.7)
CTC: 93.4 (83.6–97.9)
92.4 (81.2–97.6) 92.4 (81.6–97.6)
{Four follow-up visits at three month intervals in all projects except for Adjumani (one visit at three months only). Under the new Kiri algorithm, suspect follow-up only
occurred if the village has an observed prevalence .2%.
Values in parentheses are 95% percentile intervals.
doi:10.1371/journal.pntd.0001233.t004
Table 5. Estimated sensitivity, specificity and accuracy of staging of HAT diagnostic algorithms (worst-case scenario).
Accuracy indicator
Gamboma, Mossaka,
Nkayi, Republic of
Congo
Kiri, Sudan (old
algorithm)
Kiri, Sudan (new
algorithm)
Adjumani,
Uganda
Arua/Yumbe,
Uganda
Screening and confirmation of infection, assuming perfect follow-up of suspects{
Sensitivity if case is stage 1 (%) 91.7 (83.5–97.1) QBC: 81.8 (76.6–89.8)
CTC: 80.7 (70.5–88.9)
QBC: 59.6 (47.7–72.5)
CTC: 58.7 (46.2–72.1)
74.3 (61.1–86.3) 75.4 (62.8–86.2)
Sensitivity if case is stage 2 (%) 91.7 (83.5–97.1) QBC: 80.6 (70.4–88.7)
CTC: 79.0 (69.0–87.6)
QBC: 59.0 (47.4–71.9)
CTC: 58.1 (46.1–71.2)
75.6 (63.1–86.7) 76.1 (63.5–86.9)
Specificity (%) 97.8 (97.1–99.5) QBC: 99.6 (99.0–99.9)
CTC: 99.6 (99.0–99.9)
QBC: 99.9 (99.8–100.0)
CTC: 99.9 (99.8–100.0)
99.7 (99.2–100.0) 99.7 (99.2–100.0)
Screening and confirmation of infection, assuming no follow-up of suspects
Sensitivity if case is stage 1 (%) 85.2 (76.7–91.4) QBC: 71.1 (60.0–81.7)
CTC: 64.3 (52.3–77.0)
QBC: 53.3 (41.5–67.3)
CTC: 49.2 (36.9–64.3)
67.8 (55.6–80.3) 69.5 (56.7–81.3)
Sensitivity if case is stage 2 (%) 85.2 (76.7–91.4) QBC: 77.8 (67.4–86.6)
CTC: 74.7 (64.1–84.3)
QBC: 57.4 (45.8–70.5)
CTC: 55.6 (43.5–69.1)
73.7 (61.6–85.0) 74.6 (61.9–85.6)
Specificity (%) 97.8 (97.3–99.5) QBC: 99.6 (99.1–99.9)
CTC: 99.6 (99.1–99.9)
QBC: 99.9 (99.8–100.0)
CTC: 99.9 (99.8–100.0)
99.7 (99.2–100.0) 99.7 (99.2–100.0)
Accuracy of staging
Probability of being correctly
classified as stage 1 (%)
63.6 (44.6–74.1) QBC: 47.5 (30.5–62.4)
CTC: 45.8 (29.4–60.4)
QBC: 47.8 (31.1–62.9)
CTC: 46.6 (30.1–61.3)
47.5 (30.7–62.3) 48.0 (31.0–63.0)
Probability of being correctly
classified as stage 2 (%)
89.2 (78.9–94.8) QBC: 93.1 (83.0–97.8)
CTC: 93.7 (84.4–98.0)
QBC: 93.0 (82.7–97.8)
CTC: 93.5 (83.6–98.0)
92.9 (82.8–97.8) 92.8 (82.3–97.8)
{Four follow-up visits at three month intervals in all projects except for Adjumani (one visit at three months only). Under the new Kiri algorithm, suspect follow-up only
occurred if the village has an observed prevalence .2%.
Values in parentheses are 95% percentile intervals.
doi:10.1371/journal.pntd.0001233.t005
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The main reason for lack of sensitivity of the parasitological tests
is likely to be low parasite density. As HAT parasitaemia is known
to undulate on a daily basis, some laboratories perform repeat
blood parasitological tests so as to increase chances of detecting
parasites. Repeat tests could be a simple way to improve
sensitivity. Better evidence on the typical period between peak
and trough parasitaemia would be helpful to optimise the timing of
blood sampling. Clearly, keeping suspects for days at the treatment
centre in order to repeat tests would present serious acceptability
challenges; however, a single overnight might be feasible, and,
furthermore, the selection of suspects in whom to perform repeat
tests might also be restricted to those displaying typical signs and
symptoms of HAT.
These findings also have implications for burden estimation,
since they introduce a need to adjust observed prevalence or
incidence data for imperfect sensitivity, PPV below 100% due to
low specificity (particularly for active screening data), and unequal
stage 1 and stage 2 misclassification probabilities.
Study limitations
The literature review revealed a dearth of quality studies of
HAT test accuracy, with the exception of the CATT-wb. Many
were imprecise (only two presented a sample size rationale) and
featured less than optimal gold standards. The mAECT, used in a
variety of programmes, appears to be supported by only one large
study, and for the QBC only one study was found. This
Table 7. Prevalence of stage 1 and 2 HAT infection among persons screened passively in five MSF programmes.
Programme Stage 1 Stage 2 Total cases{ Total screened passively{ Prevalence of stage 1 Prevalence of stage 2 Overall prevalence
Gamboma 19 37 56 2028 0.9% 1.8% 2.8%
Nkayi 107 162 269 10 552 1.0% 1.5% 2.6%
Kiri 792 1269 2061 43 562 1.8% 2.9% 4.7%
Adjumani 660 1732 2392 22 175 3.0% 7.8% 10.78%
Arua-Yumbe 327 1539 1866 39 465 0.8% 3.9% 4.7%
Total 1905 4739 6644 117 782 1.6% 4.0% 5.6%
{Data on numbers screened passively are incomplete: cases are tallied here only if the number of persons screened passively during the same month is known.
doi:10.1371/journal.pntd.0001233.t007
Table 6. Predictive values and over-treatment ratio for each algorithm, at three different prevalence levels.
Accuracy indicator
Infection
prevalence (%){
Republic of
Congo{
Kiri, Southern Sudan
(old algorithm) with
QBC (with CTC")
Kiri, Southern Sudan
(new algorithm{) with
QBC (with CTC")
Adjumani,
Uganda
Arua-Yumbe,
Uganda
Baseline scenario
Positive predictive value (%) 0.1 9.3 48.4 (48.4) 100.0 (100.0) 47.2 47.3
1.0 50.8 90.5 (90.5) 100.0 (100.0) 90.0 90.0
10.0 91.9 99.1 (99.1) 100.0 (100.0) 99.0 99.0
Negative predictive value (%) 0.1 100.0 100.0 (100.0) 100.0 (100.0) 100.0 100.0
1.0 99.9 99.9 (99.9) 99.7 (99.6) 99.9 99.9
10.0 99.1 99.3 (99.3) 96.4 (96.1) 98.8 98.9
Ratio of false to true cases treated 0.1 9.8 1.1 (1.1) 0.0 (0.0) 1.1 1.1
1.0 1.0 0.1 (0.1) 0.0 (0.0) 0.1 0.1
10.0 0.1 0.01 (0.01) 0.0 (0.0) 0.01 0.01
Worst-case scenario
Positive predictive value (%) 0.1 3.7 16.9 (16.7) 37.2 (36.9) 20.0 20.2
1.0 28.1 67.2 (66.9) 85.7 (85.5) 71.6 71.8
10.0 81.1 95.8 (95.7) 98.5 (98.5) 96.5 96.6
Negative predictive value (%) 0.1 100.0 100.0 (100.0) 100.0 (100.0) 100.0 100.0
1.0 99.9 99.8 (99.8) 99.6 (99.6) 99.8 99.8
10.0 98.4 98.0 (97.8) 95.7 (95.6) 97.3 97.4
Ratio of false to true cases treated 0.1 25.8 4.9 (5.0) 1.7 (1.7) 4.0 4.0
1.0 2.6 0.5 (0.5) 0.2 (0.2) 0.4 0.4
10.0 0.2 0.04 (0.05) 0.02 (0.02) 0.04 0.04
{Assumed stage 1 to stage 2 ratio of two. Note that a ratio of 0.5 would result in almost identical estimates (data not shown), since the differences in sensitivity between
stage 1 and 2 are small and have limited influence on the PPV and NPV calculations given the low prevalence of HAT true positives.
{Assuming sensitivity and specificity without suspect follow-up, as done in practice.
"CTC values in parentheses.
doi:10.1371/journal.pntd.0001233.t006
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uncertainty may introduce information bias in the construction of
accuracy distributions. More specifically, the adoption of specific-
ity estimates for the CATT from populations from non-endemic
areas may have led to overly optimistic estimates (this was partly
addressed in the worst case scenario analysis).
Our method of constructing accuracy distributions attempts to
use existing data with minimal assumptions about their parametric
form. Arguably, meta-analysis could have been used instead, with
distributions provided by the confidence intervals of the summary
estimates from pooled studies. However, preliminary analysis
showed evidence of heterogeneity in study estimates for several
HAT tests: under these conditions, meta-analysis is discouraged.
Furthermore, there is lack of consensus on appropriate methods
for meta-analysis of diagnostic test studies [39,40].
Bayesian approaches to diagnostic accuracy estimation [41,42],
which do not require a gold standard, could be a useful alternative
to the method used here, and should also be explored.
More generally, this study’s theoretical estimates overlook some
practical realities of field work. For example, algorithms are
sometimes not performed as indicated (e.g. gland palpation may
be skipped due to heavy workload); some diagnostic decisions are
taken on clinical grounds (though probably rarely), overriding
laboratory results; and patient attrition is an issue (e.g. suspect
follow-up rates are generally low). Thus, the algorithms’ accuracy
in routine conditions may be higher or lower than our estimates,
the latter being more likely.
Conclusions
Algorithms using non-parasitological diagnosis have lower
specificity leading to varying degrees of overtreatment. Overesti-
mation of disease burden could be avoided by excluding
individuals diagnosed serologically from the case counts. Differ-
ences between active and passive screening should be considered.
Ways to improve sensitivity include follow-up of serological
suspects and repeat blood parasitological testing. This study
highlights the urgent need to pursue research on new HAT
diagnostics [43]. Improved tests should ideally replace most of the
present algorithms, and be feasible in outpatient settings (e.g. as
simple serological rapid tests), thus enabling integration of HAT
services [44]. In the present scenario of falling prevalence, any new
tests will need to be practically 100% specific. However, high
sensitivity will remain necessary to maximise the chances of
elimination. No single algorithm will be appropriate for all
epidemiological settings: rather, our study demonstrates the value
of estimating the accuracy of the algorithm as a whole, and could
be replicated in a variety of prevalence scenarios, or integrated in a
cost-effectiveness analysis that would help control programmes,
particularly those working with limited resources, optimise the use
of available diagnostics.
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